1-3 of 3
Juergen Mestan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL + leukemias

Ellen Weisberg, Laurie Catley, Renee D. Wright, Daisy Moreno, Lolita Banerji, Arghya Ray, Paul W. Manley, Juergen Mestan, Doriano Fabbro, Jingrui Jiang, Elizabeth Hall-Meyers, Linda Callahan, Jamie L. DellaGatta, Andrew L. Kung, James D. Griffin
Journal: Blood
Blood (2006) 109 (5): 2112–2120.
https://doi.org/10.1182/blood-2006-06-026377
Published: 2006
Includes: Supplemental data
Journal Articles

Bcr-Abl Resistance Screening Predicts a Limited Spectrum of Point Mutations To Be Associated with Clinical Resistance to the Abl Kinase Inhibitor AMN107.

Nikolas von Bubnoff, Jana Saenger, Paul W. Manley, Juergen Mestan, Christian Peschel, Justus Duyster
Journal: Blood
Blood (2005) 106 (11): 1983.
https://doi.org/10.1182/blood.V106.11.1983.1983
Published: 2005
Journal Articles

AMN107: In Vitro Profile of a New Inhibitor of the Tyrosine Kinase Activity of Bcr-Abl.

Juergen Mestan, Weisberg Ellen, Cowan-Jacob Sandra, Fabbro Doriano, Furet Pascal, Fendrich Gabriele, Goutte Gerard, Kempf Dominique, Gaugler Markus, Griffin D. James, Manley W. Paul
Journal: Blood
Blood (2004) 104 (11): 1978.
https://doi.org/10.1182/blood.V104.11.1978.1978
Published: 2004